期刊
PSYCHOPHARMACOLOGY
卷 239, 期 3, 页码 923-933出版社
SPRINGER
DOI: 10.1007/s00213-022-06082-z
关键词
d-amphetamine; Reward Positivity; Reinforcement learning; EEG; Mouse; Human
资金
- NIMH [UH3 MH109168]
The development of pro-cognitive therapeutics for psychiatric disorders has been hindered by translational failures. This study identifies a cross-species translational marker of reward processing and explores the impact of d-amphetamine on this marker in humans and mice. The findings suggest the role of dopamine in reward sensitivity and provide a pharmacologically valid biomarker for future research.
The bench-to-bedside development of pro-cognitive therapeutics for psychiatric disorders has been mired by translational failures. This is, in part, due to the absence of pharmacologically sensitive cognitive biomarkers common to humans and rodents. Here, we describe a cross-species translational marker of reward processing that is sensitive to the aminergic agonist, d-amphetamine. Motivated by human electroencephalographic (EEG) findings, we recently reported that frontal midline delta-band power is an electrophysiological biomarker of reward surprise in humans and in mice. In the current series of experiments, we determined the impact of parametric doses of d-amphetamine on this reward-related EEG response from humans (n = 23) and mice (n = 28) performing a probabilistic learning task. In humans, d-amphetamine (placebo, 10 mg, 20 mg) boosted the Reward Positivity event-related potential (ERP) component as well as the spectral delta-band representations of this signal. In mice, d-amphetamine (placebo, 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg) boosted both reward and punishment ERP features, yet there was no modulation of spectral activities. In sum, the present results confirm the role of dopamine in the generation of the Reward Positivity in humans, and pave the way toward a pharmacologically valid biomarker of reward sensitivity across species.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据